Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arbor's Bid For XenoPort Likely Driven By Effort To Grow Horizant

Executive Summary

With minimal unencumbered pipeline assets to offer, XenoPort's value to Arbor apparently lies in positive sales trends for the modest-selling restless legs and postherpetic neuralgia drug.

You may also be interested in...

Dr Reddy's Infuses Life Into XenoPort's Psoriasis Drug

Dr Reddy's Laboratories will take XenoPort's clinical-stage oral psoriasis NCE, XP23829, further in the US, infusing new hope in the prodrug of monomethyl fumarate (MMF) that has seen some safety issues in earlier studies and faces significant competition in the space.

GSK gives up on Horizant as XenoPort decides to go it alone

GlaxoSmithKline and XenoPort have decided to resolve their differences over Horizant (gabapentin enacarbil) extended-release tablets by terminating their collaboration. XenoPort now intends to hire a contract sales force in an attempt to do a better job on its own of commercialising the product.

XenoPort, GSK gain US FDA nod for Horizant in shingles pain

The US FDA has approved XenoPort's and GlaxoSmithKline's application for Horizant (gabapentin enacarbil) extended release as a therapy for adults to manage postherpetic neuralgia (PHN), a chronic type of neuropathic pain that can follow the resolution of shingles.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts